The digital health revolution has led to a massive increase in the amount of data available, opening new frontiers in science and medicine. AbbVie is leading one of the largest data initiatives in the industry, calledConvergence, to bring health data frommanydifferent sourcestogetherto ultimately discover and develop new medicines forpatients faster.
As part of this initiative, AbbVie recentlylaunched theAbbVie Research Collaborative, a health data platformthat enables adults anywhere in the United States to partner with AbbVie's world-class scientific researchers. Participants in the Collaborative share their real-world health dataincludingmedical records, genomic data, lifestyleand fitnessdata tohelp to tell amore complete picture of theirhealth.Real-world health data empowers researchersto findhealth and diseasepatterns they may not see within a clinical trial.
The platform will also offer individuals opportunities to participate in interventional research, uniquely tailored to their health conditions.
"As a long-time clinical researcher, I have first-hand experience seeing how difficult it can be for patients to be a part of a clinical study," said Kyle Holen,M.D., vice presidentand therapeutic area headof specialty development at AbbVie. "Through this platform, patients have the opportunity tojoin a unique research collaborative - helping to find better therapies for others like them. And for AbbVie researchers, our mission is to improve patients' lives through data-driven insights that ultimately lead to better, more personalized therapies for the patients we serve."
Participants in the AbbVie Research Collaborative gain access to an integrated visual timeline of their health that they can share with their physicians and use to make more informed medical decisions. The first cohort has launched and is now open for participants living with migraine disorder. Millions of people suffer with the debilitating condition of migraine - significantly impacting their daily lives.

Learn moreabout the AbbVie ResearchCollaborative.

Media Inquiries:

Jane Woo

jane.woo@abbvie.com

+1 (224) 864-3846

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

AbbVie Inc. published this content on 01 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 June 2022 05:11:00 UTC.